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Abstract
Introduction: Mast cells have been implicated to play a functional role in arthritis, especially in autoantibody-
positive disease. Among the cytokines involved in rheumatoid arthritis (RA), IL-17 is an important inflammatory
mediator. Recent data suggest that the synovial mast cell is a main producer of IL-17, although T cells have also
been implicated as prominent IL-17 producers as well. We aimed to identify IL-17 expression by mast cells and T
cells in synovium of arthritis patients.
Methods: Synovial samples of anticitrullinated protein antibody-positive (ACPA+) and ACPA-negative (ACPA-) RA
and osteoarthritis (OA) patients were stained for IL-17 in combination with CD117 (mast cells), CD3 (T cells) and
CD68 (macrophages). Concentrations of IL-17 in synovial fluid were determined by ELISA.
Results: The number of IL-17+ cells in synovium was comparable in all groups. Although the vast majority of IL-17+
cells are mast cells, no difference in the percentage of IL-17+ mast cells was observed. Nonetheless, levels of IL-17 in
synovial fluid were increased in ACPA+ RA patients compared to ACPA- RA and OA patients.
Conclusions: The synovial mast cell is the main IL-17+ cell in all three arthritis groups analyzed. These data are
relevant for studies aimed at blocking IL-17 in the treatment of arthritis.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic inflammation of the synovial
lining of the joint. In the majority of patients with estab-
lished RA, anticitrullinated protein antibodies (ACPAs)
can be found [1]. It is currently believed that ACPA+
and ACPA-RA are two different disease entities, each
with its own pathogenesis [2].
Several cell types of the immune system play a role in
the pathogenesis of RA. The presence of autoantibodies
and the linkage of RA to human leukocyte antigen
shared epitope alleles in ACPA+ RA indicate that the
adaptive immune system plays a prominent role.
However, cells of the innate immune system, such as
mast cells, have also been implicated in pathogenesis of
RA [3]. Indeed, the number of mast cells in synovial tis-
sue is associated with inflammatory mediators such as
histamine in synovial fluid [4].
Among the cytokines that are thought to be involved in
RA, IL-17 has recently attracted considerable attention.
IL-17 can induce production of other proinflammatory
factors such as IL-6, IL-1, TNF and matrix metalloprotei-
nases, leading to inflammation, breakdown of cartilage and
bone erosion [5]. IL-17 deficient mice are less prone to
develop experimental arthritis and blocking IL-17 can
reduce both the onset and progression in these models [6].
In RA, high levels of IL-17 were found in synovial fluid,
especially compared to OA patients [7]. The first proof-of-
concept trial indicates that neutralization of IL-17 is a
potential new target for the treatment of RA [8].
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that Th17 cells, through the production of IL-17 and
other Th17-associated cytokines, play a prominent role in
the inflamed synovium by perpetuating the inflammatory
milieu observed in arthritis [6]. Interestingly, a recent
s t u d yb yH u e b e ret al. [9] indicated that the mast cell is
the most abundant cell type expressing IL-17 in the syno-
vial tissue of 10 RA patients. However, other studies have
shown the presence of IL-17-producing T cells in RA
patients [10]. Because previous investigators have reported
that ACPA+ and ACPA- RA are distinct disease entities
[2], our aim in the present study was to analyze which cell
subsets express IL-17 in the synovial tissue of ACPA+ RA,
ACPA-RA and OA patients.
Materials and methods
Patient samples
Synovial tissues were obtained from established ACPA+
(n = 34) and ACPA- (n = 25) RA patients who had under-
gone therapeutic arthroscopic lavage of an inflamed knee
and knee or hip replacement surgery. Synovial tissues
were obtained from patients with established OA (n = 29)
who had undergone knee or hip replacement surgery.
These tissues were fixed with 4% formaldehyde in PBS,
stored in 70% ethanol and embedded in paraffin. Written
informed consent was obtained from the patients, and the
study was approved by the Leiden University Medical
Center human ethics committee.
S y n o v i a lf l u i dw a sc o l l e c t e df r o me s t a b l i s h e dA C P A +
RA patients (n = 30) and ACPA- RA patients (n =2 9 )
and from patients with established OA (n =1 4 )a n d
stored at -20°C until analysis. Patient diagnoses of RA
or OA were made according to the American College of
Rheumatology criteria [11-13].
Immunohistochemistry
Synovial tissues were treated according to the method
described by Schuerwegh et al. [14]. Slides were preincu-
bated with 10% blocking buffer (10% normal horse
serum/10% normal human serum in PBS) for 20 minutes
and stained with polyclonal goat anti-human IL-17A
(0.50 μg/mL; R&D Systems, Minneapolis, MN, USA) in
1% blocking buffer (1% normal horse serum/1% normal
human serum in PBS/1% BSA) for one hour. For control
sections, a matching isotype control (normal goat immu-
noglobulin G (IgG); Merck, Darmstadt, Germany) was
used. Detection was performed using horse a-goat biotin
(Vector Laboratories, Burlingame, CA, USA), avidin-bio-
tin-peroxidase complex (VECTASTAIN Elite ABC Kit;
Vector Laboratories) and 3, 3’-diaminobenzidine tetrahy-
drochloride-nickel chloride (Vector Laboratories).
For combined staining of IL-17 with CD117, CD3,
CD4 or CD68, slides were stained for one hour with
polyclonal rabbit anti-human CD117 (23 μg/mL; Dako,
Glostrup, Denmark), monoclonal mouse anti-human
CD3 (2.8 μg/mL; Dako), monoclonal mouse anti-human
CD4 (7 μg/mL; Dako), monoclonal mouse anti-human
CD68 (0.51 μg/mL; Dako) or matching isotype control
(rabbit polyclonal Ig and mouse IgG1; Dako) in 1%
blocking buffer. Detection of anti-CD117, anti-CD3,
anti-CD4 or anti-CD68 was performed using alkaline
phosphatase-conjugated anti-rabbit/anti-mouse Ig and
Liquid Permanent Red (EnVision™ G|2 System/AP,
Rabbit/Mouse (Permanent Red) Kit; Dako). The tissue
sections were counterstained with hematoxylin.
Stained sections were coded and randomly analyzed.
The mean number of single- and double-positive cells
in 10 high-power fields (original magnification, ×400)
was scored blindly by two observers.
Immunoassay for IL-17
Concentrations of IL-17A in synovial fluid were mea-
sured with an ELISA (PeproTech, Inc., Rocky Hill, NJ,
USA) according to the manufacturer’s instructions.
Statistical analysis
Differences between patient and control groups were ana-
lyzed using the Kruskal-Wallis and Mann-Whitney U
tests. In all tests, P < 0.05 was considered significant.
Results
To determine the expression of IL-17 by mast cells, T cells
and macrophages in synovial tissue, immunohistochemical
staining was performed in synovial tissue sections of
ACPA+ RA, ACPA- RA and OA patients (Table 1). Repre-
sentative examples of the staining are shown in Figure 1.
Isotype controls were negative (data not shown).
The median number of IL-17+ cells was slightly higher
in ACPA+ RA patients than in ACPA- RA and OA
patients, but this difference was not statistically significant
(Figure 2A). Likewise, the total number of CD117+ cells
was slightly higher in ACPA+ RA patients, although the
difference was not statistically significant. There was no
difference in the number of T cells (CD3+) or macro-
phages (CD68+) between the groups.
To identify the source of IL-17 in synovium, double-
staining of IL-17 with CD117 (mast cells), CD3 (T cells)
and CD68 (macrophages) was performed. Interestingly,
almost all IL-17-expressing cells were CD117+ in the
synovial tissue of ACPA+ and ACPA- RA patients as well
as OA patients. Only a small fraction of IL-17+ cells were
CD3+ or CD68+ (Table 1). Furthermore, there were no
differences in these percentages between the three groups.
Because CD3 can be downregulated in activated T cells,
we performed additional staining of IL-17 in combination
with CD4 in six synovium samples (Figure 1D). The med-
ian percentage (minimum-maximum range) percentage of
IL-17+ cells that were CD4+ was 0.4% (0.0% to 11.0%).
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CD4+ cells that were IL-17+ was 0.1% (0.0% to 0.7%).
Taken together, these data indicate that IL-17 in synovium
is expressed predominantly by mast cells.
Since immunohistochemistry does not reveal secretion
of IL-17, an ELISA was performed with the synovial
fluid of RA and OA patients. ACPA+ RA patients had
significantly higher levels of IL-17 in synovial fluid com-
pared to ACPA- RA and OA patients (Figure 2B).
Discussion
In this study, we have shown in a relatively large group of
59 RA and 29 OA patients that the majority of IL-17+
cells were mast cells and not T cells or macrophages.
Interestingly, levels of IL-17 in synovial fluid were
increased in ACPA+ RA patients. Because the expression
of IL-17 in synovial tissue correlates strongly with the
number of mast cells, it is conceivable that the increased
level of IL-17 in the synovial fluid of ACPA+ RA patients
results from the increased activity of mast cells in ACPA+
RA patients. Our data also show that IL-17 is not
increased in all ACPA+ RA patients. Preliminary analysis
of the characteristics of the RA patients with a high num-
ber of IL-17-producing cells shows that these patients
tend to have higher serum ACPA titers and erythrocyte
sedimentation rates at the time of diagnosis.
In this study, mast cells were identified as CD117+
cells. As described in Schuerwegh et al.[ 1 4 ] ,f l o wc y t o -
metric staining of synovial tissue revealed that all
CD117+ cells express the high-affinity IgE receptor
(FcεRI) and/or IgE. Therefore, CD117 alone can be con-
sidered a good mast cell marker in synovial tissue.
Although our results suggest that mast cells are the
most prominent producers of IL-17 in synovial tissue, a
clear limitation of this study is that only the expression of
IL-17, and not active secretion, was studied. We do not
know whether IL-17 is secreted by activated mast cells, as
we were unable to isolate viable mast cells from synovial
tissue. Nonetheless, Hueber et al. [9] showed IL-17 secre-
tion by in vitro cultured mast cells, indicating that mast
cells can readily produce IL-17. Because the samples of
synovial fluid, in which higher levels of IL-17 were found,
were from different patients than the samples of synovial
tissue, it is unclear whether the increased levels of IL-17
correlate directly to the presence of IL-17+ mast cells in
the same synovial tissue.
Our group previously found that IgE-ACPA can bind
to FcεRI on basophils and that citrullinated proteins can
directly activate basophils of ACPA+ RA patients. In
addition, an increased number of degranulated mast cells
was shown in the synovium of ACPA+ RA patients, indi-
cating a higher activity of mast cells in these patients
[14]. Because mast cells also express FcεRI, it is tempting
to speculate that mast cells are also activated by citrulli-
nated proteins present in the joint, thereby releasing IL-
17, which contributes to the inflammatory milieu present
in the inflamed synovium. However, there was no differ-
ence in the expression of IL-17 between ACPA+ and
ACPA- RA patients in our study. Therefore, it is unclear
whether the more activated state of mast cells that was
found before [14] is related to the release of IL-17, as in
o u rp r e s e n ts t u d yw ew e r ea b l et oe v a l u a t eo n l yt h e
expression of IL-17 rather than its secretion.
Several studies have provided evidence indicating that
IL-17-producing T cells in synovial tissue or fluid also
contribute to inflammation. However, these T cells are
not abundantly present in the synovial compartment.
Indeed, even after strong nonspecific T-cell triggering,
only a small minority of CD4+ T cells (about 1% to
10%) obtained from synovial fluid or synovial tissue
Table 1 Expression of IL-17 by mast cells, T cells and macrophages in synovial tissue
Demographics ACPA+ RA (n = 34) ACPA- RA (n = 25) OA (n = 29) P value
Age (years) 55 (32 to 80) 63 (19 to 80) 67 (42 to 83)
Gender (females/males) 22/12 14/11 21/8
Disease duration (years) 7 (0 to 28) 8 (0 to 24) Unknown
Median IL-17+ cells 21 (0 to 118) 12 (1 to 61) 17 (0 to 50) 0.381
IL-17+ mast cells (%) 97 (40 to 100) 96 (0 to 100) 93 (0 to 100) 0.969
IL-17+ T cells (%) 0 (0 to 100) 0 (0 to 24) 2 (0 to 49) 0.558
IL-17+ MØ (%) 0 (0 to 78) 4 (0 to 100) 1 (0 to 58) 0.382
Median MCs 28 (0 to 123) 19 (0 to 92) 25 (0 to 76) 0.198
MCs (CD117+) expressing IL-17 (%) 91 (13 to 100) 83 (0 to 100) 96 (4 to 100) 0.599
T cells (CD3+), n 21 (0 to 592) 10 (0 to 115) 11 (0 to 265) 0.609
T cells (CD3+) expressing IL-17 (%) 0 (0 to 60) 0 (0 to 66) 1 (0 to 78) 0.149
MØ (CD68+), n 71 (1 to 390) 53 (1 to 302) 66 (2 to 231) 0.634
MØ (CD68+) expressing IL-17 (%) 0 (0 to 16) 0 (0 to 14) 0 (0 to 11) 0.689
ACPA: anticitrullinated protein antibody; MC: mast cell; MØ: macrophage; OA: osteoarthritis; RA: rheumatoid arthritis. Results are expressed as medians (minimum-
maximum). Mast cells are defined as CD117+ cells, T cells are defined as CD3+ cells and macrophages are defined as CD68+ cells.
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Page 3 of 7Figure 1 Expression of IL-17 by immunohistochemistry. (A) Double-staining of IL-17 (black) and CD117+ mast cells (pink). (B) Double-
staining of IL-17 (black) and CD68+ macrophages (pink). (C) Double-staining of IL-17 (black) and CD3+ T cells (pink). (D) Double-staining of IL-17
(black) and CD4 (pink). Representative examples are shown. In insets in parts (A) through (D), arrows indicate double-positive cells and
arrowheads indicate single IL-17+ cells. The magnification of inset images are made digitally, and are 2× the magnification of the original figure
which is made through a 400× magnification.
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Page 4 of 7Figure 2 IL-17 in synovial tissue and synovial fluid. (A) Number of IL-17+ cells in synovial tissue of ACPA- and ACPA+ RA and OA patients.
The results are expressed as the number of cells assessed in 10 high-power fields at ×400 magnification. (B) Levels of IL-17 in synovial fluid
determined by ELISA. *P < 0.05 and **P < 0.01, both indicating statistically significant differences. ACPA, anticitrullinated protein antibody; OA,
osteoarthritis; RA, rheumatoid arthritis.
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Page 5 of 7produce IL-17, as shown by flow cytometry [10,15-17].
Furthermore, the antigen specificity of these Th17 cells
in synovium is unknown; therefore, these cells can also
be innocent bystanders that do not contribute to inflam-
mation in the joint in vivo.I nt w os t u d i e si nw h i c h
immunohistochemical staining was performed, IL-17+
cells were identified as CD3+ cells. However, it is
unclear how these results relate to our study, as in those
previous studies cells were identified using single stain-
ing of consecutive sections and the positive cells in the
overlying sections were not quantified, making it diffi-
cult to compare these contradictory results with the
results of our study [18,19]. Two other studies in which
microscopic analysis was performed showed that almost
no CD3+ T cells in the synovium expressed IL-17. In
agreement with our study, in one of these studies the
cell types that did express IL-17 were found to be
mainly mast cells [9]. However, the other study in which
no CD3+ T cells were shown to express IL-17 identified
IL-17+ cells as being mainly neutrophils and neutrophil
precursors in the synovium of the facet joints [20].
Because we found the mast cells to be the main cell
subset expressing IL-17 in synovium from the knee, it is
possible that the cells expressing IL-17 might be differ-
ent, depending on the site of the joint.
Because the production of IL-17 is highly restricted by
transcriptional control via RORgT (retinoid acid recep-
tor-related orphan receptor gt), which is also known to
regulate the production of other Th17-associated cyto-
kines, mast cells might also produce other Th17-related
cytokines, such as IL-22. Furthermore, because mast
cells can produce many other cytokines as well, blocking
the activation of mast cells, such as by preventing their
activation via the FcεRI through anti-IgE treatment,
might lead to even more profound effects than blocking
IL-17 alone in arthritis patients. Indeed, blocking TNF is
a very successful therapy in RA, and mast cells are
known to be important producers of TNF [21].
Conclusions
Our results show that IL-17 is expressed mainly by mast
cells in the synovial tissue of both ACPA+ and ACPA-
RA patients, as well as in OA patients. Selective activa-
tion of mast cells in ACPA+ RA patients might be
responsible for the increased levels of IL-17 in synovial
fluid. These data are relevant for new targeted therapies
in arthritis, such as IL-17 blockade or the inhibition of
mast cell activation.
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